Metabolic Syndrome, Cardiovascular Disease and the Hair Growth Cycle: Addressing hair growth disruptions using Nourkrin® with Marilex® as a proteoglycan replacement therapy: A concise review

Abstract

Alopecia is associated with an increased risk of coronary heart disease, and it appears that there is a relationship between the degree of hair loss and the risk of coronary heart disease, meaning, the greater the severity of alopecia, the greater the risk of coronary heart disease. Alopecia is also associated with an increased risk of hypertension, hyperinsulinemia, insulin resistance, metabolic syndrome as well as elevated serum total cholesterol and triglyceride levels.Read more......

It is not invisible! A case report of 2 patients with scalp Lichen Planopilaris mimicking Androgenic Alopecia

Lichen planopilaris (LPP), a morphological variant of Lichen Planus known as specific of the scalp, is a rare, difficult-to-treat, chronic, inflammatory skin condition resulting in cicatricial alopecia, which can be eventually permanent irreversible [1]. It has been described for the first time by Pringle in 1895 [2] and placed in the lymphocytic disease group by the North American Hair Research Society (NAHRS) [3]. The causes of this disease are not well clarified but it seems to act as an autoimmune disorder probably triggered by drugs, metal exposure, stress, pollution, contacts sensitizers or infection [4]. Epidemiological data report that about 0.5-1% of the population is affected by Lichen Planus and in particular, adult women result as the most affected population by LPP (ratio 1.8:1) [5,7], on people aged between 40-60 years and more frequently in Caucasian and Indian population than Asian ones [7,8] Its typical manifestation is multifocal areas of alopecia on the central scalp, usually accompanied by perifollicular erythema, hyperkeratosis, and subjective symptoms such as pruritus or pain [9]. Three different variants of LPP are normally recognized [3,9]: classic LPP, frontal fibrosing alopecia (FFA) [10] and Graham-Little Piccardi Lassueur Syndrome [11]. A fourth variant, known as fibrosing alopecia in a pattern distribution (FAPD) could be added if considering some cases of patients with androgenetic alopecia in which lesions identical to those seen in LPP were found [12].Read more.....

Lifestyle Diseases and the Hair Growth Cycle: A multidisciplinary approach using Nourkrin® with Marilex®, a proteoglycan replacement therapy, for anagen induction and maintenance

Introduction

Introduction of Hair loss-related disease such as andogenetic alopecia
Androgentic alopecia (AGA) is a chronic immune-mediated inflammatory skin disease characterised by uncontrolled proliferation of keratinocytes, activated dendritic cells, release of proinflammatory cytokines and the recruitment of T cells to the skin. Androgenetic alopecia affects both sexes [1,2]. The condition is characterised by the progressive loss of terminal hairs on the scalp in a characteristic distribution. In men, the anterior scalp, mid scalp, temporal scalp and vertex of the scalp are typical sites of involvement. ‘Male balding’ and ‘male pattern hair loss’ are additional terms used to refer to this condition. In women, the condition is characterised by a general decrease in the hair’s volume, a noticeable widening of the mid-line part and/or a see-through appearance on the top of the scalp. The term ‘female pattern hair loss’ (FPHL) is used to refer to this condition.Read more.....

Clinical significance of Vibration Anesthesia on reducing pain of Ring-Block (Subcutaneous Injections) in the patients undergoing Hair Restoration Surgery

Pain is a complex phenomenon which is unpleasant. Different cosmetic procedures are associated with varying degrees of pain. Various modalities are adopted to decrease the severity of pain. The commonly used is the administration of analgesics (opioid or non-steroidal). The pain is carried to the brain by pain fibres. There are various theories about the pain [1,2]. Many attempts have been undertaken to find the modalities which decrease the perception of pain by the brain. The famous ‘gate theory’ was proposed in 1965 by Melzack et al. [3]. It was proposed that the pain experience can be reduced by the activation of nerve fibres that conduct non-toxic stimuli. The theory suggested that the stimulation of larger diameter fibres (A-beta) can close a neural ‘gate’ to nocioceptive signals and can reduce the perception of the pain. The ‘gate’ is proposed to lie within the spinal cord/brainstem and inhibits the transmission of nocioceptive action potentials to higher centres in the central nervous system [4]. The “post-synaptic inhibitory and fascilitatory mechanism” provide a basis for explaining the pain reducing strategies such as rubbing the painful area or applying cold or vibration to decrease the perception of the pain. Various topical irritants used in a few ‘magic’ creams also work on the same principle.Read more....